Skip to content

Optimization of Yinxielingpian in the Treatment pf Psoriasis Vulgaris: a Randomized Controlled Trial

Yinxielingpian in the Treatment of Psoriasis Vulgaris: a Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-10000836
Enrollment
Unknown
Registered
2010-04-13
Start date
2009-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis vulgaris

Interventions

Group B:Placebo
Group A:Optimization of Yinxielingpian

Sponsors

Guangdong Provincial Hospital of Chinese Traditional Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 72 Years

Inclusion criteria

Inclusion criteria: 1. Male and female aged 18 to 72 years old; 2. Patients who meet the psoriasis vulgaris diagnosis creteria; 3. To be able to and willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women, and menorrhagia women; 2. Allergic to this drug ingredient; 3. Other types of psoriasis; 4. Taking steroids over the past 2 weeks, and / or oral administration of retinoic acid drugs, steroids outside over the past 1 week; 5. Associated with cardiovascular, cerebrovascular, liver, kidney and hematopoietic system of primary and serious diseases, or mental illness; 6. Patients who judged by researchers as unsuitable for this study.

Design outcomes

Primary

MeasureTime frame
Poriasis Area and Severity Index;

Secondary

MeasureTime frame
Physician's Global Assessment;Itching Visual Analog Scale;Life Quality Index;

Countries

China

Contacts

Public ContactChuanjian Lu
luchuanjian888@vip.sina.com+86 20 81887233-31223

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026